JHVEPhoto
The FDA has accepted Alvotech (NASDAQ:ALVO
) and Teva’s (NYSE:TEVA) Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria.
Review of the applications is expected to by completed in Q4 2025, according to
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445064010/image_1445064010.jpg?io=getty-c-w750
2025-01-27 15:59:54
